Pacira BioSciences: FDA to Review Exparel in Lower Extremity Procedures
March 29 2023 - 08:59AM
Dow Jones News
By Colin Kellaher
Pacira BioSciences Inc. on Wednesday said the U.S. Food and Drug
Administration accepted its application seeking expanded approval
of its local anesthetic Exparel to cover lower-extremity surgical
procedures.
The Tampa, Fla., pain-management company said the agency set a
target action date of Nov. 13 for the application, which covers
single-dose sciatic nerve block in the popliteal fossa as well as
femoral nerve block in the adductor canal.
Pacira reported 2022 net product sales of nearly $537 million
for Exparel, which is currently approved for infiltration, fascial
plane block and as an interscalene brachial plexus nerve block for
post-surgical pain management, and said it expects sales of $570
million to $580 million for the drug this year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 29, 2023 08:44 ET (12:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Pacira BioSciences (NASDAQ:PCRX)
Historical Stock Chart
From May 2023 to May 2023
Pacira BioSciences (NASDAQ:PCRX)
Historical Stock Chart
From May 2022 to May 2023
